BioSight
Companies
Centessa Pharmaceuticals plc logo

CNTA

NASDAQALTRINCHAM, CHESHIRE, X0
Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc is a biopharmaceutical company developing orexin agonist molecules, including cleminorexton, ORX142, and ORX489, for therapeutic applications. Centessa's pipeline candidates are currently in early-stage clinical development, ranging from Phase 1 first-in-human trials to Phase 2 studies. Centessa is subject to a proposed acquisition by Eli Lilly and Company.

Price history not yet available for CNTA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar